Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Jul 1;9(7):811–820. doi: 10.1242/dmm.024166

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016. Published by The Company of Biologists Ltd

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

PMC Copyright notice

Fig. 4. — BRAF^V600E inhibitor treatment of primary zebrafish melanoma transplants. (A) MHC caspers were transplanted with MiniCoopR:eGFP control melanoma tumors. The top panel shows the tumor burden of a representative zebrafish prior to DMSO treatment at day 10 and after a 2-week treatment with DMSO at day 24. The bottom panel shows the tumor burden of a representative zebrafish prior to Vemurafenib treatment at day 10 and after a 2-week treatment regimen with Vemurafenib at day 24. (B) Average percent change from baseline of tumor area based on pigmentation in a cohort with n=14 or n=15 in the DMSO or Vemurafenib-treated arm, respectively. Two-tailed paired t-test was performed for statistical analysis. Data represented as mean±s.d. of three replicates. (C) Waterfall plots depict the range of response for the experimental cohorts, DMSO and Vemurafenib. The response was quantified by percent change of tumor area from baseline. (D) MHC caspers were transplanted with MiniCoopR:MEK1DD melanoma tumors. The top panel shows the tumor burden of a representative zebrafish prior to DMSO treatment at day 10 and after a 2-week treatment with DMSO at day 24. The bottom panel shows the tumor burden of a representative zebrafish prior to Vemurafenib treatment at day 10 and after a 2-week treatment regimen with Vemurafenib at day 24. (E) Average percent change from baseline of tumor area based on pigmentation in a cohort with n=10 or n=12 in the DMSO or Vemurafenib-treated arm, respectively. Two-tailed paired t-test was performed for statistical analysis. Data represented as mean±s.d. of two replicates. (F) Waterfall plots depict the range of response for the experimental cohorts, DMSO and Vemurafenib. The response was quantified by percent change of tumor area from baseline.